Certainly, 89Zr(IV)-conjugates have been gaining significant importance in nuclear medicine for the diagnosis of different types of cancer and this makes DFOB and its analogues important clinical immunoPET imaging probes; some representative clinical-stage 89Zr(IV)/DFOB-conjugates include: 89Zr(IV)/DFOB-J591, targeting metastatic prostate cancer, 89Zr(IV)/DFOB-trastuzumab and 89Zr(IV)/DFOB-pertuzumab, for imaging HER2/neu expression, and 89Zr(IV)/DFOB-bevacizumab, for imaging vascular endothelial growth factor [29,39,88,92]. This evidence concerns the gene ERBB2 and metastatic prostate carcinoma.